Synonyms: ALTUVIIIO® | BIVV-001 | BIVV001 | Fc-VWF-XTEN
efanesoctocog alfa is an approved drug (FDA (2023))
Compound class:
Peptide
Comment: Efanesoctocog alfa (BIVV-001) is a recombinant protein that fuses factor VIII (FVIII) to a human IgG1 Fc domain. It was designed as a long-acting FVIII replacement therapy [4]. Pharmacodynamic effects of efanesoctocog alfa (clot formation) are identical to those elicited by recombinant FVIII [1].
|
Classification | |
Compound class | Peptide |
Approved drug? | Yes (FDA (2023)) |
International Nonproprietary Names | |
INN number | INN |
11314 | efanesoctocog alfa |
Synonyms |
ALTUVIIIO® | BIVV-001 | BIVV001 | Fc-VWF-XTEN |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 701 |
Other databases | |
GtoPdb PubChem SID | 491299868 |
Search PubMed clinical trials | efanesoctocog alfa |
Search PubMed titles | efanesoctocog alfa |
Search PubMed titles/abstracts | efanesoctocog alfa |